Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMT 504

Next Previous
Drug Profile

IMT 504

Alternative Names: IMT504

Latest Information Update: 06 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunotech SA; Mid-Atlantic BioTherapeutics
  • Class Oligodeoxyribonucleotides
  • Mechanism of Action B cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rabies
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Rabies
  • No development reported Breast cancer; Chronic lymphocytic leukaemia; Diabetes mellitus; Hepatitis B; Influenza virus infections; Neuropathic pain; Osteoporosis; Sepsis

Most Recent Events

  • 06 Oct 2022 Curative Biotech announces intentions to obtain marketing approval for Rabies from the US FDA, by 2024 (Curative Biotech pipeline, October 2022)
  • 07 Oct 2021 Curative Biotech acquires the worldwide rights for the development of IMT 504 from Mid-Atlantic BioTherapeutics for the treatment of rabies
  • 28 May 2021 No recent reports of development identified for preclinical development in Diabetes-mellitus in Argentina (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top